Peptide Medicine
DSIP (Delta Sleep-Inducing Peptide): Evidence, Uses, and Safety
Medically reviewed by HealthRX.com Medical Team · Last reviewed
What is DSIP?
DSIP is a peptide of nine amino acids, first isolated in 1977 by a Swiss research group from the brain blood of rabbits during sleep-like brain activity. When infused into other rabbits it increased slow-wave (delta) brain activity, which gave the peptide its name.
Despite nearly 50 years of study, no DSIP gene and no specific DSIP receptor have ever been identified. It is best described as an investigational research peptide, not an approved drug or a recognized hormone. [1][6]
How does DSIP work?
Honestly, the mechanism is not established. Because no receptor has been found, every proposed action is inferred. Older studies suggest DSIP may modulate sleep, calm the stress (HPA) axis, and interact indirectly with GABA and glutamate signaling, but none of this is settled.
DSIP is described as a sleep modulator rather than a sedative, said to act more when sleep is disturbed than in normal sleepers. It is also reported to be broken down quickly in the blood, which raises questions about how much reaches the brain when given by injection. [3][6]
What does the research on DSIP show?
The evidence is weak and dated. Most human studies are small and from the 1970s to early 1990s, and results are inconsistent. The best-controlled sleep trial found only weak effects. A 2006 review concluded the sleep-factor idea remains poorly documented. Modern rigorous trials do not exist.
- Sleep: a 1992 double-blind study in chronic insomniacs found weak effects and concluded DSIP was unlikely to be of major benefit. [5]
- Withdrawal: small uncontrolled reports from the 1980s described symptom relief, never confirmed in modern trials. [4]
- Modern verdict: a 2006 review called DSIP an unresolved riddle, with no gene, no receptor and weak evidence. [6]
- Honest framing: current interest is driven more by the wellness market than by new clinical science.
How is DSIP used and dosed?
There is no established, evidence-based dose. Older research used intravenous dosing. Wellness clinics discuss small subcutaneous microgram doses taken at night before sleep, in short cycles. These figures are reported, not validated, and product quality in the unregulated market is not assured.
| Setting | Route | Notes |
|---|---|---|
| Older research | Intravenous | Small studies; not a modern protocol |
| Wellness clinics | Subcutaneous, evening | Reported microgram ranges; not standardized or validated |
Is DSIP safe, and what are the side effects?
Short-term, small, old studies reported DSIP was generally well tolerated. Minor effects like headache, dizziness or grogginess have been described. The real story is the unknowns: there is no long-term safety data, no large safety database, and no quality control over gray-market products.
- Reported minor effects include headache, dizziness and injection-site reactions.
- No long-term human safety data exists.
- Gray-market products may have purity, sterility or dosing problems.
- Safety in pregnancy, in complex patients or with chronic use is unknown.
Is DSIP legal and FDA approved?
DSIP is not FDA approved for any use, and there is no official dose. It has been sold mainly as a research chemical. In 2026, under the name Emideltide, it was scheduled for FDA compounding advisory review for the Section 503A bulk list, but a review is not approval and the outcome is not certain.
Being reviewed for, or even added to, the compounding bulk list is not the same as FDA drug approval. As of 2026 DSIP remains unapproved and the review outcome is pending. [6]
How does DSIP compare with other peptides?
| DSIP | Epitalon | Approved sleep medicines | |
|---|---|---|---|
| Type | Research peptide | Research peptide | FDA-approved drugs |
| Evidence | Weak, dated | Limited | Large modern trials |
| Dosing | Not standardized | Not standardized | Defined |
| FDA approved | No | No | Yes |
Frequently asked questions
Does DSIP actually make you sleep?
Some small, mostly old studies reported modest improvements in disturbed sleep, but the best controlled trial found the effect weak and probably not meaningful. The evidence that DSIP dependably improves sleep is limited and mixed.
Is DSIP FDA approved?
No. DSIP is not approved for any condition, and there is no official dose. It was reviewed in 2026 for possible compounding-pharmacy use, but that review is not approval. Most product sold is unregulated research chemical.
How strong is the science behind DSIP?
Weak and dated. Most human studies are from the 1970s to early 1990s, with small samples and often no control group. After decades of research, no DSIP gene or receptor has been found, and modern rigorous trials do not exist.
Is DSIP safe?
Short-term, small, old studies reported it was generally well tolerated, with minor effects like headache. But there is no long-term safety data and no quality control over gray-market products. Tolerated in small studies is not the same as proven safe.
How is DSIP used and dosed?
There is no established, evidence-based dose. Older research used intravenous dosing; wellness clinics discuss small subcutaneous doses at night. Because none of this is standardized or regulated, any dosing figures should be treated as unverified reports, not guidance.
Citations
- Schoenenberger GA, Monnier M. Characterization of a delta-electroencephalogram (sleep)-inducing peptide. Proc Natl Acad Sci USA. 1977;74(3):1282-1286.
- Schoenenberger GA, et al. The delta EEG (sleep)-inducing peptide (DSIP): amino-acid sequence, synthesis and activity. Pflugers Arch. 1978;376(2):119-129.
- Graf MV, Kastin AJ. Delta-sleep-inducing peptide (DSIP): a review. Neurosci Biobehav Rev. 1984;8(1):83-93.
- Dick P, Grandjean ME, Tissot R. Treatment of withdrawal symptoms with delta sleep-inducing peptide. Neuropsychobiology. 1983;10(4):205-208.
- Bes F, et al. Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients: a double-blind study. Neuropsychobiology. 1992;26(4):193-197.
- Kovalzon VM, Strekalova TV. Delta sleep-inducing peptide (DSIP): a still unresolved riddle. J Neurochem. 2006;97(2):303-309.
This guide is educational and is not a substitute for individualized medical advice. DSIP is prescription-only and requires evaluation by a licensed provider.